SLC31A1 and non-small cell lung carcinoma: Thus, our findings that the genetic interaction between SLC31A1 and ABCG2 polymorphisms was associated with clinical outcomes of NSCLC patients receiving platinum-based chemotherapy may have important implications for the pharmacoethnicity of platinating agents in cancer chemotherapy.